MX2021015935A - Formas de sal de acido bempedoico y metodos para utilizar el mismo. - Google Patents

Formas de sal de acido bempedoico y metodos para utilizar el mismo.

Info

Publication number
MX2021015935A
MX2021015935A MX2021015935A MX2021015935A MX2021015935A MX 2021015935 A MX2021015935 A MX 2021015935A MX 2021015935 A MX2021015935 A MX 2021015935A MX 2021015935 A MX2021015935 A MX 2021015935A MX 2021015935 A MX2021015935 A MX 2021015935A
Authority
MX
Mexico
Prior art keywords
methods
forms
bempedoic acid
same
acid salt
Prior art date
Application number
MX2021015935A
Other languages
English (en)
Spanish (es)
Inventor
Mohamed Abdelnasser
Richard Copp
Christopher M Cimarusti
Chengxiang Liu
Original Assignee
Esperion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=71528020&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2021015935(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Esperion Therapeutics Inc filed Critical Esperion Therapeutics Inc
Publication of MX2021015935A publication Critical patent/MX2021015935A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/04Preparation of carboxylic acids or their salts, halides or anhydrides from carboxylic acid halides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00Preparation of sulfones; Preparation of sulfoxides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/26Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/36Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/09Preparation of carboxylic acids or their salts, halides or anhydrides from carboxylic acid esters or lactones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/285Polyhydroxy dicarboxylic acids having five or more carbon atoms, e.g. saccharic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/347Saturated compounds containing more than one carboxyl group containing keto groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • C07C67/30Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/307Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of halogen; by substitution of halogen atoms by other halogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • C07C67/30Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/31Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of functional groups containing oxygen only in singly bound form
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • C07C67/30Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/313Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of doubly bound oxygen containing functional groups, e.g. carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/62Halogen-containing esters
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Crystallography & Structural Chemistry (AREA)
MX2021015935A 2019-06-21 2020-06-19 Formas de sal de acido bempedoico y metodos para utilizar el mismo. MX2021015935A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962864873P 2019-06-21 2019-06-21
PCT/US2020/038624 WO2020257573A1 (en) 2019-06-21 2020-06-19 Salt forms of bempedoic acid and methods for using the same

Publications (1)

Publication Number Publication Date
MX2021015935A true MX2021015935A (es) 2022-04-26

Family

ID=71528020

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021015935A MX2021015935A (es) 2019-06-21 2020-06-19 Formas de sal de acido bempedoico y metodos para utilizar el mismo.
MX2021015936A MX2021015936A (es) 2019-06-21 2020-06-19 Metodos para preparar acido bempedoico y composiciones del mismo.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021015936A MX2021015936A (es) 2019-06-21 2020-06-19 Metodos para preparar acido bempedoico y composiciones del mismo.

Country Status (13)

Country Link
US (10) US12344578B2 (enExample)
EP (3) EP3986860A1 (enExample)
JP (3) JP2022537049A (enExample)
KR (3) KR20250143358A (enExample)
CN (3) CN112437765A (enExample)
AU (3) AU2020295503A1 (enExample)
BR (2) BR112021025964A2 (enExample)
CA (2) CA3144372A1 (enExample)
ES (1) ES3032779T3 (enExample)
HU (1) HUE072061T2 (enExample)
IL (3) IL288909A (enExample)
MX (2) MX2021015935A (enExample)
WO (2) WO2020257571A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022537049A (ja) 2019-06-21 2022-08-23 エスペリオン・セラピューティクス・インコーポレイテッド ベンペド酸の製造方法及びその組成物
EP4038045A1 (en) 2019-10-03 2022-08-10 Synthon B.V. Crystalline forms of bempedoic acid
US20230036336A1 (en) * 2019-12-06 2023-02-02 Synthon B.V. Crystalline forms of sodium salt of bempedoic acid
CN111559961A (zh) * 2020-05-26 2020-08-21 杭州科巢生物科技有限公司 一种贝派地酸晶型及其制备方法
WO2021255180A1 (en) * 2020-06-19 2021-12-23 Synthon B.V. Salts of bempedoic acid
CN112521282A (zh) * 2020-12-02 2021-03-19 苏州汉德创宏生化科技有限公司 一种贝派地酸中间体及其合成方法
WO2022149161A1 (en) * 2021-01-05 2022-07-14 Dr. Reddy's Laboratories Limited Process for preparation of bempedoic acid and its intermediates
EP4346795B1 (en) 2021-06-02 2025-03-05 Esperion Therapeutics, Inc. Compositions containing bempedoic acid alone or in combination with tolvaptan for use in a method for treating autosomal dominant polycystic kidney disease (adpkd)
CN115504914B (zh) * 2021-06-23 2024-05-07 武汉武药科技有限公司 一种贝派地酸中间体的制备方法
CN114436837B (zh) * 2021-12-27 2024-02-20 甘李药业股份有限公司 一种贝派地酸中间体的纯化方法
WO2023187833A1 (en) * 2022-03-30 2023-10-05 Enaltec Labs Private Limited A novel salt of bempedoic acid
WO2024151311A1 (en) 2023-01-09 2024-07-18 Esperion Therapeutics, Inc. Methods of treatment using bempedoic acid
CN116589341A (zh) * 2023-04-14 2023-08-15 苏州汉德创宏生化科技有限公司 一种抗高血酯药物中间体的制备方法
WO2025196155A1 (en) 2024-03-20 2025-09-25 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
WO2025196153A1 (en) 2024-03-20 2025-09-25 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
WO2025196154A1 (en) 2024-03-20 2025-09-25 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
WO2025238159A1 (en) 2024-05-16 2025-11-20 Astrazeneca Ab Combination therapy comprising azd0780 and ezetimibe

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3152148A (en) 1963-01-03 1964-10-06 Dow Chemical Co Preparation of comenic and pyromeconic acids
US3441605A (en) 1965-02-17 1969-04-29 Wallace & Tiernan Inc Diketo-dicarboxylic acids and salts and preparation thereof by alkaline oxidation
GB1196595A (en) 1966-12-21 1970-07-01 Geigy Uk Ltd Preparation of a Lactone
GB1196594A (en) 1966-12-21 1970-07-01 Geigy Uk Ltd Improvements in and relating to the production of Sebacic Acid
GB1196597A (en) 1966-12-21 1970-07-01 Geigy Uk Ltd Preparation of an Oxido-Cyclodecene
GB1196596A (en) 1966-12-21 1970-07-01 Geigy Uk Ltd Preparation of a hydroxysebacic acid
FR1545224A (fr) 1966-12-21 1968-11-08 Geigy Ag J R Procédé de préparation de l'acide sébacique
GB1196598A (en) 1966-12-21 1970-07-01 Geigy Uk Ltd Preparation of a Ketosebacic Acid
US3773946A (en) 1969-09-02 1973-11-20 Parke Davis & Co Triglyceride-lowering compositions and methods
US3930024A (en) 1969-09-02 1975-12-30 Parke Davis & Co Pharmaceutical compositions and methods
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
US4281200A (en) 1979-08-30 1981-07-28 The Dow Chemical Company Catalytic process for converting oxazolidinones to their corresponding aminoalcohols
JPS5639033A (en) 1979-09-04 1981-04-14 Kao Corp Alpha-mono(methyl-branched alkyl glyceryl ether and skin cosmetic containing the same
IL64542A0 (en) 1981-12-15 1982-03-31 Yissum Res Dev Co Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them
IT1164254B (it) 1983-05-30 1987-04-08 Luso Farmaco Inst 3-(3-idrossibutossi)-1-butanolo e suo metodo di preparazione
JPS59232811A (ja) 1983-06-16 1984-12-27 Sumitomo Chem Co Ltd 芳香族ポリアミドイミド樹脂成形体の製造方法
JPS60136512A (ja) 1983-12-26 1985-07-20 Eisai Co Ltd 脂質代謝改善剤
DE3423166A1 (de) 1984-06-22 1986-01-02 Epis S.A., Zug Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
US4896344A (en) 1984-10-15 1990-01-23 Grady John K X-ray video system
US4634119A (en) 1985-07-11 1987-01-06 Pesthy Paul K Resilient exercise machine with body support platform
US4714762A (en) 1986-10-31 1987-12-22 Warner-Lambert Company Antiarteriosclerotic substituted benzimidazol-2-yl-and 3H-imidazo[4,5-b]pyridin-2-yl-phenoxy-alkanoic acids and salts and esters thereof
US5225439A (en) 1987-01-28 1993-07-06 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5428062A (en) 1987-01-28 1995-06-27 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US4758880A (en) 1987-03-27 1988-07-19 The Grass Valley Group, Inc. Video matte generator
JP2999579B2 (ja) 1990-07-18 2000-01-17 武田薬品工業株式会社 Dnaおよびその用途
US5254589A (en) 1991-10-15 1993-10-19 Warner-Lambert Company Sulfonyl urea and carbamate ACAT inhibitors
IL109431A (en) 1993-05-14 2001-01-11 Warner Lambert Co Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds
US5420339A (en) 1993-11-22 1995-05-30 Warner-Lambert Company Alpha-aryl or heteroaryl-substituted amide ester ACAT inhibitors
JP2937012B2 (ja) 1994-04-08 1999-08-23 時久 増田 角筒包装袋の製造方法及び装置
US5578639A (en) 1994-07-01 1996-11-26 Warner-Lambert Company PLA2 inhibitors and their use for inhibition of intestinal cholesterol absorption
US5504073A (en) 1994-07-01 1996-04-02 Warner-Lambert Company PLA2 inhibitors and their use for inhibition of intestinal cholesterol absorption
SE9500778D0 (sv) 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
US5648387A (en) 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
CN1217656C (zh) 1995-11-02 2005-09-07 沃尼尔·朗伯公司 用于调节脂浓度的方法和药物组合物
JP4139448B2 (ja) 1996-08-13 2008-08-27 信越化学工業株式会社 α−ブロモ,ω−クロロアルカンの製造方法
US5807846A (en) 1996-11-14 1998-09-15 Warner-Lambert Company Phosphonamide ACAT inhibitors
IL119971A (en) 1997-01-07 2003-02-12 Yissum Res Dev Co Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids
US6093744A (en) 1997-04-21 2000-07-25 Warner-Lambert Company N-acyl sulfamic acid esters useful as hypocholesterolemic agents
IL121165A0 (en) 1997-06-26 1997-11-20 Yissum Res Dev Co Pharmaceutical compositions containing carboxylic acids and derivatives thereof
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
TR200001522T2 (tr) 1997-11-25 2000-12-21 Warner-Lambert Company Lipoprotein oksidasyonunun inhibisyonu.
BR0009520A (pt) 1999-04-01 2002-06-11 Esperion Therapeutics Inc Composto, método para sintetizar o mesmo, composição, metódos para o tratramento ou prevenção, em um paciente, de doença cardiovascular, dislipidemia, dislipoproteinemia, distúrbio de metabolismo de glucose, doença de alzheimer, sìndrome x ou sìndrome metabólica, septicemia, distúrbio trombótico, distúrbio associado com receptor ativado por proliferador de peroxissoma, obesidade, pancreatite, hipertensão, doença renal, câncer, inflamação, impotência, para reduzir o teor de gordura de carne de gado bovino, e, para reduzir o teor de colesterol de ovos de aves
MXPA03003022A (es) 2000-10-11 2003-07-14 Esperion Therapeutics Inc Compuestos de sulfuro y disulfuro y composiciones para el control del colesterol y usos relacionados.
CA2425678A1 (en) 2000-10-11 2002-04-18 Jean-Louis H. Dasseux Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
JP2004529069A (ja) 2000-10-11 2004-09-24 エスペリオン セラピューティクス,インコーポレイテッド コレステロール管理用のエーテル化合物及び組成物ならびに関連する使用
EP1326822A2 (en) 2000-10-11 2003-07-16 Esperion Therapeutics Inc. Ketone compounds and compositions for cholesterol management and related uses
US7304093B2 (en) 2000-10-11 2007-12-04 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
US7053046B2 (en) 2001-12-21 2006-05-30 Mcgrath Kevin Peptide activators of VEGF
US7119221B2 (en) 2003-01-23 2006-10-10 Esperion Therapeutics, Inc. Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses
AU2003304703A1 (en) 2003-12-24 2005-08-03 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
JP4553181B2 (ja) 2004-03-25 2010-09-29 株式会社サタケ 残留農薬分析方法
US8209479B2 (en) 2007-07-18 2012-06-26 Google Inc. Memory circuit system and method
MX367352B (es) 2012-01-06 2019-08-16 Gemphire Therapeutics Inc Metodos para reducir el riesgo de padecer una enfermedad cardiovascular.
US9662307B2 (en) * 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US20160058751A1 (en) 2013-03-28 2016-03-03 Cellworks Group, Inc. Composition and method for treating cancer
WO2015018060A1 (en) * 2013-08-09 2015-02-12 Agios Pharmaceuticals, Inc. Crystalline forms of therapeutically active compounds and use thereof
KR102370582B1 (ko) 2015-03-13 2022-03-04 에스페리온 테라피유틱스 인코포레이티드 Etc1002 및 에제티미브를 포함하는 고정 용량 조합 및 제형 및 심혈관 질환의 치료 또는 이의 위험의 감소 방법
MA41793A (fr) 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
WO2017023165A1 (en) 2015-08-04 2017-02-09 Dezima Pharma B.V. Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and an atp citrate lyase inhibitor – ampk activator
WO2018148417A1 (en) 2017-02-08 2018-08-16 Esperion Therapeutics, Inc. Triplet combination formulations and methods of treating or reducing the risk of cardiovascular disease
AR111786A1 (es) 2017-05-11 2019-08-21 Gemphire Therapeutics Inc Composiciones de gemcabeno y su uso
US20180338922A1 (en) 2017-05-26 2018-11-29 Esperion Therapeutics, Inc. Fixed dose formulations
CN107628975B (zh) * 2017-09-17 2019-10-29 贵州医科大学 赖氨酸衍生物类组蛋白去乙酰化酶抑制剂及其合成和应用
CN109721486A (zh) * 2017-10-31 2019-05-07 鲁南制药集团股份有限公司 一种8-羟基-2,2,14,14-四甲基-十五烷二酸的合成方法
RU2020129191A (ru) 2018-02-16 2022-03-16 Эсперион Терапеутикс, Инк. Композиции с замедленным высвобождением бемпедоевой кислоты
EP3666750A1 (en) * 2018-12-10 2020-06-17 Sandoz AG Crystalline form of bempedoic acid
EP3906231A2 (en) * 2018-12-31 2021-11-10 Lupin Limited Novel salts and polymorphic form of bempedoic acid
JP2022537049A (ja) 2019-06-21 2022-08-23 エスペリオン・セラピューティクス・インコーポレイテッド ベンペド酸の製造方法及びその組成物
US20230036336A1 (en) * 2019-12-06 2023-02-02 Synthon B.V. Crystalline forms of sodium salt of bempedoic acid
WO2022149161A1 (en) 2021-01-05 2022-07-14 Dr. Reddy's Laboratories Limited Process for preparation of bempedoic acid and its intermediates

Also Published As

Publication number Publication date
AU2020296094A1 (en) 2022-01-27
CN112437766A (zh) 2021-03-02
ES3032779T3 (en) 2025-07-24
AU2020295503A1 (en) 2022-01-27
US11613511B2 (en) 2023-03-28
CA3144371A1 (en) 2020-12-24
US12398087B2 (en) 2025-08-26
US12344578B2 (en) 2025-07-01
IL288997A (en) 2022-02-01
EP3986859A1 (en) 2022-04-27
US20210139405A1 (en) 2021-05-13
CN115429784A (zh) 2022-12-06
US11760714B2 (en) 2023-09-19
AU2025203232A1 (en) 2025-05-29
CA3144372A1 (en) 2020-12-24
KR20220024816A (ko) 2022-03-03
WO2020257571A1 (en) 2020-12-24
EP4438114A3 (en) 2024-12-25
BR112021025928A2 (pt) 2022-05-10
EP3986859B1 (en) 2025-04-30
US20240286987A1 (en) 2024-08-29
US20220281795A1 (en) 2022-09-08
KR20250143358A (ko) 2025-10-01
US20240317665A1 (en) 2024-09-26
IL288909A (en) 2022-02-01
US20230183160A1 (en) 2023-06-15
US20210139401A1 (en) 2021-05-13
US12404227B2 (en) 2025-09-02
JP2022537049A (ja) 2022-08-23
JP2025032197A (ja) 2025-03-11
HUE072061T2 (hu) 2025-10-28
KR20220024815A (ko) 2022-03-03
US20220388937A1 (en) 2022-12-08
US20230141635A1 (en) 2023-05-11
BR112021025964A2 (pt) 2022-05-24
IL324076A (en) 2025-12-01
JP2022536979A (ja) 2022-08-22
US20240182396A1 (en) 2024-06-06
CN112437765A (zh) 2021-03-02
US20230250043A1 (en) 2023-08-10
EP4438114A2 (en) 2024-10-02
EP3986860A1 (en) 2022-04-27
AU2020296094B2 (en) 2025-02-06
MX2021015936A (es) 2022-04-26
US11926584B2 (en) 2024-03-12
US11407705B2 (en) 2022-08-09
WO2020257573A1 (en) 2020-12-24
US11987548B2 (en) 2024-05-21

Similar Documents

Publication Publication Date Title
MX2021015935A (es) Formas de sal de acido bempedoico y metodos para utilizar el mismo.
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
CL2019000979A1 (es) Composiciones y anticuerpos anti-lag-3.
CL2019003049A1 (es) Compuestos de heteroarilo bicíclicos 6-6 fusionados y su uso como inhibidores de lats.
CL2019001328A1 (es) Proteínas quiméricas insecticidas, composiciones que las comprenden, y estrategias para el control de plagas de lepidópteros basadas en su uso.
CO2018010316A2 (es) Inmunomoduladores
CO2019011809A2 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak
CO2018005640A2 (es) Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria
CO2018003500A2 (es) Anticuerpos anti-pd-1 y composiciones
BR112019004100A2 (pt) compostos de biarila úteis como imunomoduladores
DOP2017000048A (es) Compuestos aminopirimidinilo como inhibidores de jak.
CL2021000514A1 (es) Dimetilaminoazetidinaminas como inhibidores de jak
MX2017006167A (es) Compuestos que interactúan con glicanos y métodos de uso.
MX2016009625A (es) Proteinas quimericas tipo fosfatasa alcalina.
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
CO2018005954A2 (es) Compuestos heteroaromáticos como inhibidores de btk
CL2017000368A1 (es) Compuestos fusionados de 11 miembros y fungicidas agrícolas/hortícolas que los contienen
CO2019001181A2 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
AR113803A1 (es) Compuesto de pirimidina como inhibidor de jak quinasas
CO2019011546A2 (es) Compuestos y métodos para el tratamiento de enfermedades parasitarias
CL2017001073A1 (es) 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos
UY36145A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
CL2021001198A1 (es) Compuestos heteroaromáticos como inhibidores de vanina
MX2018004295A (es) Compuestos, composiciones farmáceuticas y métodos de uso de agonistas de ppar.